Jacobs Marc D, Caron Paul R, Hare Brian J
Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, Massachusetts 02139, USA.
Proteins. 2008 Mar;70(4):1451-60. doi: 10.1002/prot.21633.
We report a clustering of public human protein kinase structures based on the conformations of two structural elements, the activation segment and the C-helix, revealing three discrete clusters. One cluster includes kinases in catalytically active conformations. Each of the other clusters contains a distinct inactive conformation. Typically, kinases adopt at most one of the inactive conformations in available X-ray structures, implying that one of the conformations is preferred for many kinases. The classification is consistent with selectivity profiles of several well-characterized kinase inhibitors. We show further that inhibitor selectivity profiles guide kinase classification. For example, selective inhibition of lck among src-family kinases by imatinib (Gleevec) suggests that the relative stabilities of inactive conformations of lck are different from other src-family kinases. We report the X-ray structure of the lck/imatinib complex, confirming that the conformation adopted by lck is distinct from other structurally-characterized src-family kinases and instead resembles kinases abl1 and kit in complex with imatinib. Our classification creates new paths for designing small-molecule inhibitors.
我们基于激活环和C螺旋这两个结构元件的构象,报道了公共人类蛋白激酶结构的聚类分析,揭示了三个离散的聚类。一个聚类包括处于催化活性构象的激酶。其他每个聚类都包含一种独特的无活性构象。通常,激酶在现有的X射线结构中最多采用一种无活性构象,这意味着许多激酶更倾向于其中一种构象。该分类与几种特征明确的激酶抑制剂的选择性概况一致。我们进一步表明,抑制剂选择性概况可指导激酶分类。例如,伊马替尼(格列卫)对src家族激酶中lck的选择性抑制表明,lck无活性构象的相对稳定性与其他src家族激酶不同。我们报道了lck/伊马替尼复合物的X射线结构,证实lck所采用的构象与其他已进行结构表征的src家族激酶不同,而是类似于与伊马替尼形成复合物的abl1激酶和kit激酶。我们的分类为设计小分子抑制剂开辟了新途径。